Assignee
PRINCIPIA BIOPHARMA INC
US·48 granted patents·47 pending applications·407 citations·filing 2008–2025
Top patents by PatentIndex Score
95 records- 0199US8673925B1Tyrosine kinase inhibitorsPRINCIPIA BIOPHARMA INC·Filed 2013·Granted Mar 18, 2014·114 cites·22 claims
- 0298US9688676B2Tyrosine kinase inhibitorsPRINCIPIA BIOPHARMA INC·Filed 2017·Granted Jun 27, 2017·32 cites·3 claims
- 0398US9090621B2Tyrosine kinase inhibitorsPRINCIPIA BIOPHARMA INC·Filed 2014·Granted Jul 28, 2015·29 cites·8 claims
- 0498US8759358B1Tyrosine kinase inhibitorsPRINCIPIA BIOPHARMA INC·Filed 2013·Granted Jun 24, 2014·22 cites·16 claims
- 0597US8962635B2Tyrosine kinase inhibitorsPRINCIPIA BIOPHARMA INC·Filed 2014·Granted Feb 24, 2015·17 cites·1 claims
- 0697US8957080B2Tyrosine kinase inhibitorsPRINCIPIA BIOPHARMA INC·Filed 2013·Granted Feb 17, 2015·19 cites·24 claims
- 0797US8946241B2Tyrosine kinase inhibitorsPRINCIPIA BIOPHARMA INC·Filed 2014·Granted Feb 3, 2015·18 cites·8 claims
- 0896US11827656B2Immunoproteasome inhibitorsPRINCIPIA BIOPHARMA INC·Filed 2021·Granted Nov 28, 2023·2 cites·27 claims
- 0996US11369613B2Salts and solid form of a BTK inhibitorPRINCIPIA BIOPHARMA INC·Filed 2020·Granted Jun 28, 2022·3 cites·3 claims
- 1095US10456403B2Salts and solid form of a BTK inhibitorPRINCIPIA BIOPHARMA INC·Filed 2018·Granted Oct 29, 2019·9 cites·17 claims
- 1195US10092569B2Salts and solid form of a BTK inhibitorPRINCIPIA BIOPHARMA INC·Filed 2015·Granted Oct 9, 2018·13 cites·10 claims
- 1295US8940744B2Pyrazolopyrimidine compounds as kinase inhibitorsPRINCIPIA BIOPHARMA INC·Filed 2014·Granted Jan 27, 2015·26 cites·30 claims
- 1394US9994576B2Substituted pyrazolo[3,4-d]pyrimidines as kinase inhibitorsPRINCIPIA BIOPHARMA INC·Filed 2016·Granted Jun 12, 2018·14 cites·22 claims
- 1493US11225493B2Immunoproteasome inhibitorsPRINCIPIA BIOPHARMA INC·Filed 2018·Granted Jan 18, 2022·4 cites·32 claims
- 1593US9266895B2Substituted pyrazolo[3,4-d]pyrimidines as kinase inhibitorsPRINCIPIA BIOPHARMA INC·Filed 2013·Granted Feb 23, 2016·17 cites·10 claims
- 1692US10828307B2Salts and solid form of a BTK inhibitorPRINCIPIA BIOPHARMA INC·Filed 2019·Granted Nov 10, 2020·3 cites·4 claims
- 1792US10533013B2Substituted pyrazolo[3,4-d]pyrimidines as kinase inhibitorsPRINCIPIA BIOPHARMA INC·Filed 2018·Granted Jan 14, 2020·8 cites·10 claims
- 1891US11040980B2Substituted pyrazolo[3,4-d]pyrimidines as kinase inhibitorsPRINCIPIA BIOPHARMA INC·Filed 2019·Granted Jun 22, 2021·3 cites·18 claims
- 1990US9567334B2Quinolone derivatives as fibroblast growth factor receptor inhibitorsPRINCIPIA BIOPHARMA INC·Filed 2016·Granted Feb 14, 2017·6 cites·16 claims
- 2089US11078199B2Quinolone derivatives as fibroblast growth factor receptor inhibitorsPRINCIPIA BIOPHARMA INC·Filed 2019·Granted Aug 3, 2021·2 cites·15 claims
- 2189US10485797B2Treatment of pemphigusPRINCIPIA BIOPHARMA INC·Filed 2015·Granted Nov 26, 2019·10 cites·18 claims
- 2288US9572811B2Treatment of dry eyePRINCIPIA BIOPHARMA INC·Filed 2013·Granted Feb 21, 2017·16 cites·9 claims
- 2387US12162882B2Quinolone derivatives as fibroblast growth factor receptor inhibitorsPRINCIPIA BIOPHARMA INC·Filed 2023·Granted Dec 10, 2024·0 cites·11 claims
- 2487US10899760B2Processes for preparing an FGFR inhibitorPRINCIPIA BIOPHARMA INC·Filed 2020·Granted Jan 26, 2021·2 cites·12 claims
- 2587US9815834B2Quinolone derivatives as fibroblast growth factor receptor inhibitorsPRINCIPIA BIOPHARMA INC·Filed 2015·Granted Nov 14, 2017·4 cites·16 claims
- 2686US2025197402A1Tyrosine Kinase InhibitorsPRINCIPIA BIOPHARMA INC·Filed 2024·Application pending·0 cites
- 2785US11154563B2Immunoproteasome inhibitorsPRINCIPIA BIOPHARMA INC·Filed 2018·Granted Oct 26, 2021·2 cites·28 claims
- 2884US10538518B2Processes for preparing an FGFR inhibitorPRINCIPIA BIOPHARMA INC·Filed 2016·Granted Jan 21, 2020·2 cites·7 claims
- 2984US10538517B2Quinolone derivatives as FGFR inhibitorsPRINCIPIA BIOPHARMA INC·Filed 2016·Granted Jan 21, 2020·3 cites·23 claims
- 3084US2024174676A1Pyrazolopyrimidine compounds as kinase InhibitorsPRINCIPIA BIOPHARMA INC·Filed 2023·Application pending·0 cites
- 3183US10294223B2Quinolone derivatives as fibroblast growth factor receptor inhibitorsPRINCIPIA BIOPHARMA INC·Filed 2017·Granted May 21, 2019·2 cites·15 claims
- 3281US12336999B2Modified release formulations of 2-[3-[4-amino-3-(2-fluoro-4-phenoxy-phenyl) pyrazolo[3,4-d] pyrimidin-1-yl]piperidine-1-carbonyl]-4-methyl-4-[4-(oxetan-3-yl) piperazin-1-yl]pent-2-enenitrilePRINCIPIA BIOPHARMA INC·Filed 2023·Granted Jun 24, 2025·0 cites·20 claims
- 3381US2022370459A1Salts and Solid Form of a BTK InhibitorPRINCIPIA BIOPHARMA INC·Filed 2022·Application pending·0 cites
- 3481US2023151012A1Tyrosine kinase inhibitorsPRINCIPIA BIOPHARMA INC·Filed 2022·Application pending·0 cites
- 3579US2024309000A1Process for Preparing an FGFR InhibitorPRINCIPIA BIOPHARMA INC·Filed 2024·Application pending·0 cites
- 3678US12410176B2Crystalline forms of 2-[3-[4-amino-3-(2-fluoro-4-phenoxy-phenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]piperidine-1-carbonyl]-4-methyl-4-[4-(oxetan-3-yl)piperazin-1-yl]pent-2-enenitrilePRINCIPIA BIOPHARMA INC·Filed 2023·Granted Sep 9, 2025·0 cites·1 claims
- 3778US12312370B2Immunoproteasome inhibitorsPRINCIPIA BIOPHARMA INC·Filed 2023·Granted May 27, 2025·0 cites·20 claims
- 3877US9630963B2Quinolone derivatives as fibroblast growth factor inhibitorsPRINCIPIA BIOPHARMA INC·Filed 2014·Granted Apr 25, 2017·3 cites·14 claims
- 3976US2025381193A1Modified Release Formulations of 2-[3-[4-Amino-3-(2-Fluoro-4-Phenoxy-Phenyl) Pyrazolo[3,4-D] Pyrimidin-1-yl]Piperidine-1-Carbonyl]-4-Methyl -4-[4-(Oxetan-3-yl)Piperazin-1-yl]Pent-2-EnenitrilePRINCIPIA BIOPHARMA INC·Filed 2025·Application pending·0 cites
- 4076US2022073522A1Substituted Pyrazolo[3,4-d]Pyrimidines as Kinase InhibitorsPRINCIPIA BIOPHARMA INC·Filed 2021·Application pending·0 cites
- 4175US2021292323A1Quinolone Derivatives as Fibroblast Growth Factor InhibitorsPRINCIPIA BIOPHARMA INC·Filed 2021·Application pending·0 cites
- 4274US12281110B2Processes for preparing an FGFR inhibitorPRINCIPIA BIOPHARMA INC·Filed 2021·Granted Apr 22, 2025·0 cites·19 claims
- 4374US10946008B2Treatment of pemphigusPRINCIPIA BIOPHARMA INC·Filed 2019·Granted Mar 16, 2021·1 cites·22 claims
- 4473US12281120B2Crystalline forms of 2-[3-[4-amino-3-(2-fluoro-4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]piperidine-1-carbonyl]-4,4-dimethylpent-2-enenitrilePRINCIPIA BIOPHARMA INC·Filed 2023·Granted Apr 22, 2025·0 cites·8 claims
- 4572US2025368656A1Crystalline Forms of 2-[3-[4-Amino-3-(2-Fluoro-4-Phenoxy-Phenyl)-1H-Pyrazolo[3,4-D]Pyrimidin-1- YL]Piperidine-1-Carbonyl]-4-Methyl-4-[4-(Oxetan-3-YL)Piperazin-1-YL]Pent-2- EnenitrilePRINCIPIA BIOPHARMA INC·Filed 2025·Application pending·0 cites
- 4672US2025221999A1Methods for Treating Immune Thrombocytopenia by Administering (R)-2-[3-[4-Amino-3-(2-Fluoro-4-Phenoxy- Phenyl) Pyrazolo[3,4-D]Pyrimidin-1-YL]Piperidine-1-Carbonyl]-4-Methyl-4-[4-(Oxetan-3-YL)Piperazin-1-YL]Pent-2-EnenitrilePRINCIPIA BIOPHARMA INC·Filed 2024·Application pending·0 cites
- 4771US2021171526A1Tyrosine Kinase InhibitorsPRINCIPIA BIOPHARMA INC·Filed 2020·Application pending·0 cites
- 4871US2025099470A1Topical Pharmaceutical Compositions Comprising 2-[3-[4-Amino-3-(2-Fluoro-4-Phenoxy-Phenyl)-1H-Pyrazolo[3,4-D]Pyrimidin-1-YL]Piperidine-1-Carbonyl]-4,4-Dimethylpent-2-EnenitrilePRINCIPIA BIOPHARMA INC·Filed 2024·Application pending·0 cites
- 4970US2025262193A1Therapeutic Tyrosine Kinase Inhibitors For Multiple Sclerosis and Myasthenia GravisPRINCIPIA BIOPHARMA INC·Filed 2024·Application pending·0 cites
- 5070US2023399330A1Solid Forms of 2-[3-[4-Amino-3-(2-Fluoro-4-Phenoxy-Phenyl)Pyrazolo[3,4-d]Pyrimidin-1-YL] Piperidine-1-Carbonyl]-4-Methyl-4-[4-(Oxetan-3-YL)Piperazin-1-YL]Pent-2-EnenitrilePRINCIPIA BIOPHARMA INC·Filed 2023·Application pending·0 cites
Showing the top 50 of 95 patent records by PatentIndex Score.
Join the waitlist — get patent alerts
Get an alert when PRINCIPIA BIOPHARMA INC files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →